According to Seagen 's latest financial reports the company's current revenue (TTM) is $2.30 B. In 2022 the company made a revenue of $1.96 B an increase over the years 2021 revenue that were of $1.57 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $2.30 B | 17.22% |
2022 | $1.96 B | 24.65% |
2021 | $1.57 B | -27.63% |
2020 | $2.17 B | 137.32% |
2019 | $0.91 B | 40.02% |
2018 | $0.65 B | 35.76% |
2017 | $0.48 B | 15.33% |
2016 | $0.41 B | 24.15% |
2015 | $0.33 B | 17.45% |
2014 | $0.28 B | 6.5% |
2013 | $0.26 B | 27.73% |
2012 | $0.21 B | 122.43% |
2011 | $94.77 M | -11.81% |
2010 | $0.10 B | 106.81% |
2009 | $51.96 M | 47.48% |
2008 | $35.23 M | 57.16% |
2007 | $22.42 M | 124.09% |
2006 | $10 M | 2.54% |
2005 | $9.75 M | 45.61% |
2004 | $6.7 M | 32.16% |
2003 | $5.07 M | 201.15% |
2002 | $1.68 M | 514.14% |
2001 | $0.27 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 2,442.96% | ๐บ๐ธ USA |
AbbVie ABBV | $54.31 B | 2,261.29% | ๐บ๐ธ USA |
Biogen BIIB | $9.83 B | 327.57% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | 1,856.48% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | 1,545.36% | ๐ฌ๐ง UK |
Spectrum Pharmaceuticals
SPPI | $25.72 M | -98.88% | ๐บ๐ธ USA |
ImmunoGen
IMGN | $0.28 B | -87.50% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $6.88 M | -99.70% | ๐บ๐ธ USA |